Ibrutinib treatment for CLL yields different PFS in population-based setting
After presenting the initial results of a study investigating the efficacy of ibrutinib for chronic lymphocytic leukemia (CLL) within a population-based setting, Lina van der Straten, PhD, of the Albe...
Author: VJHemOnc
Added: 07/23/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 23, 2018 Category: Cancer & Oncology Source Type: podcasts
AML metabolism may be the key to successful treatment
Cancerous cells in acute myeloid leukemia (AML) utilize different metabolic pathways to normal cells. Using this difference in their biology, Giovanni Martinelli, MD, of the Istituto Scientifico Romag...
Author: VJHemOnc
Added: 07/23/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 23, 2018 Category: Cancer & Oncology Source Type: podcasts
Promising results for quizartinib in R/R AML
The treatment of acute myeloid leukemia (AML) patients who have relapsed has, to date, been quite difficult as there has been a notable lack of knowledge behind the cause of the changes leading to rel...
Author: VJHemOnc
Added: 07/23/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 23, 2018 Category: Cancer & Oncology Source Type: podcasts
Promising outlook for frontline blinatumomab in Ph+ ALL
Acute lymphoblastic leukemia (ALL) is currently treated with a regimen of drugs that, while effective to an extent, could be improved upon. In this interview, Giovanni Martinelli, MD, of the Istituto ...
Author: VJHemOnc
Added: 07/23/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 23, 2018 Category: Cancer & Oncology Source Type: podcasts
MRD in AML: prognoses, transplant and treatment planning
Measurable residual disease (MRD) has become a crucial part of treatment planning and prognosis construction in many hematological diseases; however, in acute myeloid leukemia (AML), heterogeneity of ...
Author: VJHemOnc
Added: 07/23/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 23, 2018 Category: Cancer & Oncology Source Type: podcasts
Treatment challenges for young CLL patients
Treating young patients with chronic lymphocytic leukemia (CLL) poses a unique set of challenges because treatment has to be effective for many years, and even decades. Matthew Davids, MD, MSc, of the...
Author: VJHemOnc
Added: 07/23/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 23, 2018 Category: Cancer & Oncology Source Type: podcasts
Duvelisib and FCR: a recipe for success in CLL
Chronic lymphocytic leukemia (CLL) treatment is experiencing a shift away from chemotherapy in favor of novel agents. FCR chemotherapy, however, has shown impressive responses, and even curative effec...
Author: VJHemOnc
Added: 07/23/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 23, 2018 Category: Cancer & Oncology Source Type: podcasts
Gilteritinib in FLT3 mutated AML patients
Mark Levis, MD, PhD, talks about new information about gilteritinib in FLT3 mutated acute myeloid leukemia (AML) at ASCO 2018.
Author: obr
Added: 07/20/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 20, 2018 Category: Cancer & Oncology Source Type: podcasts
Measurable residual disease in relapsed/refractory AML
Mark Levis, MD, PhD, explains the impact of measurable residual disease in the clinical outcomes of patients with relapsed or refractory acute myeloid leukemia (AML) at ASCO 2018
Author: obr
Added: 07/20/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 20, 2018 Category: Cancer & Oncology Source Type: podcasts
Combination therapies in CLL: ibrutinib and venetoclax
There has been a multitude of novel, exciting therapies within the field of chronic lymphocytic leukemia (CLL), explains Stephen Devereux, FRCP, FRCPath, PhD, of Kings College Hospital NHS Foundation...
Author: VJHemOnc
Added: 07/20/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 20, 2018 Category: Cancer & Oncology Source Type: podcasts
A future study linking tumor genetics with CLL dynamics
New genetic sequencing techniques could yield profound insights into disease progression in chronic lymphocytic leukemia (CLL). Niamph Appleby, MB, BAO, BCh, MRCPI, FRCPath, from the the Royal Marsden...
Author: VJHemOnc
Added: 07/20/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 20, 2018 Category: Cancer & Oncology Source Type: podcasts
1st line therapy in AML patients with FLT3 mutations
Mark Levis, MD, PhD, explains the key factors influencing 1st line therapy in acute myeloid leukemia(AML) patients with FLT3 mutations at ASCO 2018.
Author: obr
Added: 07/19/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 19, 2018 Category: Cancer & Oncology Source Type: podcasts
Moving away from chemotherapy in CLL
The drive to find treatment options for chronic lymphocytic leukemia (CLL) with lower toxicities means clinicians are relying less and less on chemotherapy. Here, William Wierda, MD, PhD, of the MD An...
Author: VJHemOnc
Added: 07/18/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 18, 2018 Category: Cancer & Oncology Source Type: podcasts
Novel agents in CLL: could they make chemotherapy redundant?Novel agents in CLL: could they make chemotherapy redundant?
Chronic lymphocytic leukemia (CLL) is usually fairly non-aggressive; however, there remain certain patients who have a rapidly progressing disease and require effective treatment. Currently, chemother...
Author: VJHemOnc
Added: 07/18/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 18, 2018 Category: Cancer & Oncology Source Type: podcasts
Combining MRD with genetic knowledge in ALL
Measurable residual disease (MRD) is arguably the most useful single prognostic tool we have within the field of acute lymphoblastic leukemia (ALL), discusses Anthony Moorman, PhD, of Newcastle Univer...
Author: VJHemOnc
Added: 07/18/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 18, 2018 Category: Cancer & Oncology Source Type: podcasts
